BIO 📈 Bio-Rad Laboratories - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0905722072
BIO: Instruments, Systems, Reagents, Consumables, Test Kits, Informatics Systems
Bio-Rad Laboratories, Inc. is a prominent player in the life science research and clinical diagnostic products industry, with a global presence spanning the United States, Europe, Asia, Canada, and Latin America. The company's operations are divided into two primary segments: Life Science and Clinical Diagnostics. Through these segments, Bio-Rad develops, manufactures, and markets a wide range of instruments, systems, reagents, and consumables designed to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids. These products cater to various markets, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety.
The company's product portfolio is extensive, encompassing test systems, informatics systems, test kits, and specialized quality controls tailored for hospitals, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories. Bio-Rad's products are designed to support a broad range of applications, from basic research to clinical diagnostics, and are backed by a robust support system. The company's distribution network is equally impressive, with products being sold through a direct sales force, as well as through distributors, agents, brokers, and resellers. This multi-channel approach enables Bio-Rad to effectively reach its diverse customer base and provide timely support and services.
With a history dating back to 1952, Bio-Rad Laboratories, Inc. has established itself as a trusted and reliable partner in the life science research and clinical diagnostic communities. Headquartered in Hercules, California, the company has built a strong reputation for delivering high-quality products and innovative solutions that meet the evolving needs of its customers. As a publicly traded company listed on the New York Stock Exchange (NYSE) under the ticker symbol BIO, Bio-Rad is committed to transparency and accountability, with its common stock (ISIN: US0905722072) being classified under the GICS Sub Industry: Life Sciences Tools & Services. For more information, investors and customers can visit the company's website at https://www.bio-rad.com.
Additional Sources for BIO Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BIO Stock Overview
Market Cap in USD | 9,572m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 1966-01-01 |
BIO Stock Ratings
Growth 5y | -21.1% |
Fundamental | -19.3% |
Dividend | - |
Rel. Strength Industry | -29.4 |
Analysts | 4/5 |
Fair Price Momentum | 297.94 USD |
Fair Price DCF | 251.85 USD |
BIO Dividends
No Dividends PaidBIO Growth Ratios
Growth Correlation 3m | -27% |
Growth Correlation 12m | 31.4% |
Growth Correlation 5y | -64.1% |
CAGR 5y | -2.19% |
CAGR/Mean DD 5y | -0.07 |
Sharpe Ratio 12m | 0.10 |
Alpha | -21.46 |
Beta | 0.87 |
Volatility | 37.36% |
Current Volume | 77.9k |
Average Volume 20d | 178.6k |
As of December 30, 2024, the stock is trading at USD 330.87 with a total of 77,926 shares traded.
Over the past week, the price has changed by +0.76%, over one month by -2.84%, over three months by -1.11% and over the past year by +2.47%.
Neither. Based on ValueRay Fundamental Analyses, Bio-Rad Laboratories is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -19.27 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BIO as of December 2024 is 297.94. This means that BIO is currently overvalued and has a potential downside of -9.95%.
Bio-Rad Laboratories has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy BIO.
- Strong Buy: 2
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, BIO Bio-Rad Laboratories will be worth about 327.7 in December 2025. The stock is currently trading at 330.87. This means that the stock has a potential downside of -0.97%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 404.3 | 22.2% |
Analysts Target Price | 523.6 | 58.2% |
ValueRay Target Price | 327.7 | -1% |